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Exposure ofthe lung to silica particles results
in inflammation, damage to the respiratory
epithelium and interstitial matrix, and fibro-
sis (1). Numerous studies in rats have shown
that an inflammatory and pneumotoxic
response develops after acute intratracheal
exposure to silica (2-4). This response is
characterized as a rapidly progressive disease
associated with extensive epithelial damage
and abundant airway debris. Airspaces are
filled with exudate composed ofserum and
lung proteins, surfactant lipids, and many
inflammatory cells (5).
Amiodarone, an iodinated, benzofuran
derivative with a cationic, amphiphilic struc-
ture, is approved for use in the treatment of
life-threatening ventricular tachyarrhyth-
mias. The administration of amiodarone to
humans and laboratory animals has led to a
pulmonary response characterized initially
by the development of phospholipidosis
(6-8). Morphologically, phospholipidosis
appears as lysosomally derived lamellar
inclusion bodies in many cells ofthe lungs,
including AMs (9,10), endothelial and
interstitial cells (6,11), bronchiolar epithelial
cells (12), and alveolar type II cells (6,13).
Of these cell types, the AMs appear to be
the most susceptible to amiodarone treat-
ment. As well as containing inclusions, these
cells become hypertrophic, taking on a
foamy appearance, and accumulating in ele-
vated numbers in the alveoli. These altered
cells have been referred to as "foamyAMs."
The pulmonary phospholipidosis
induced by amiodarone is associated with
impaired phospholipid catabolism. It has
been demonstrated that this drug, and its
principal metabolite desethylamiodarone,
inhibit lysosomal phospholipase A, and A2
activities (14-17). Due to this disruption in
phospholipid breakdown, treatment of rats
with amiodarone significantly increases the
concentration of total phospholipid in
whole lung and AMs (9,18,195. In our pre-
vious studies (9,19), it was shown that this
development of phospholipidosis was both
dose and time dependent as well as
reversible.
Vallyathan et al. (20) have demonstrated
that the surface properties ofthe silica parti-
cles may be responsible for the cytotoxicty
caused by exposure to silica. A variety of
substances such as phospholipid, organo-
silane, aluminum lactate, and polyvinylpyri-
dine-N-oxide, have been used in a number
of in vitro studies in an attempt to coat the
silica and reduce its cytotoxicity (21-25).
Based on these in vitrostudies, our hypothe-
sis was that the increase in phospholipid lev-
els within the lungs after the induction of
phospholipidosis will protect them from
damage caused by the exposure to cytotoxic
particles.
In this study, we induced pulmonary
phospholipidosis in rats using amiodarone
and determined that this increase in intra-
cellular or extracellular phospholipid
reduced the acute toxic response in the
lungs when challenged intratracheally with
silica dust. In the measurement of the
inflammatory response of silica for our
study, a number ofcellular and biochemical
endpoints in the bronchoalveolar lavage flu-
ids were measured. Lavage of the bron-
choalveolar region collects epithelial lining
fluid of the conducting airways and alveoli,
the sites of pulmonary contact for instilled
silica particles (4). Previous studies have
indicated analysis of the bronchoalveolar
lavage fluid is a sensitive means ofcharacter-
izing acute inflammatory responses within
the lungs (26-28).
In this investigation, we also attempted
to determine the mechanism by which pul-
monary phospholipidosis protects the lungs
from silica damage. To simulate our in vivo
experiments in this study, we used an in
vitro system where viability of amiodarone-
induced foamy AMs and normal, control
AMs was measured after incubation with
native silica or silica treated with Survanta, a
commercially available pulmonary surfac-
tant. Survanta is a natural bovine lung
extract containing phospholipids, neutral
lipids, fatty acids, and surfactant-associated
proteins (29).
Materials and Methods
Amiodarone was a gift from Wyeth-Ayerst
Research (Princeton, New Jersey).
Crystalline Min-U-Sil silica (U. S. Silica
Corp., Berkley Springs, West Virginia) was
a gift from Val Vallyathan, National
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Institute for Occupational Safety and
Health. Purity of the silica was determined
by automated X-ray diffractrometry and
was 99.5% alpha quartz. Size fraction of<5
pm in diameter was made by a centrifugal
airflow particle classifier. Of this fraction,
98% was <5 pm with a median area equiva-
lent diameter of 3.5 pm as estimated by
automated scanning electron microscopic
image analysis. Survanta (Ross Laboratories,
Columbus, Ohio) samples were supplied by
the West Virginia University Department
of Pharmaceutical Services. It is the policy
of the pharmacy that, after use in human
patients, any remaining reconstituted sam-
ples of Survanta in opened vials is discard-
ed. The Survanta samples used in this inves-
tigation represented unused drug that was
ready to be discarded. After use by the phar-
macy, the unused surfactant samples were
frozen at -20'C and stored until ready for
experimentation. Enzyme reagents were
purchased from Sigma Chemical Company
(St. Louis, Missouri). Other chemicals used
in this study were from Fisher Chemical
Company (Pittsburgh, Pennsylvania).
The experimental design will be
described briefly, then detailed in subse-
quent sections. Male Fischer 344 rats were
treated by oral gavage with amiodarone or
water (pair-fed controls) for 14 days. We
intratracheally instilled silica suspended in
saline into one-half of each of the two
treatment groups. The remaining animals
received an intratracheal instillation of the
saline vehicle. Thus, for these experiments,
four study groups were used. The groups
and the designations used in this study are
as follows: 1) amiodarone-treated + silica:
A-SI; 2) water-treated + silica: W-SI; 3)
amiodarone-treated + saline: A-SA; and 4)
water-treated + saline: W-SA. Broncho-
alveolar lavage was performed on the ani-
mals 1 and 14 days after the instillation
exposures. We assessed three basic indica-
tors ofpulmonary damage: a total and dif-
ferential cell count to characterize the cel-
lular aspects ofinflammation; total protein
to quantify increased permeability of the
bronchoalveolar-capillary barrier; and the
activity of the lysosomal enzyme f3-glu-
curonidase to detect activated or lysed
phagocytes. To ensure that a phospholipi-
dotic condition was induced by the amio-
darone treatment, the total phospholipid
content ofthe cells and lavage fluid recov-
ered from the lungs was also measured.
We obtained Male Fischer 344 rats
weighing 200-250 g from Hilltop Lab-
oratories (Scottdale, Pennsylvania). Rats
were given a conventional laboratory diet
(Purina Chow Pellets) and tap water ad
libitum during a 5-day acclimation period.
We then treated the rats for 14 days with
150 mg amiodarone/kg of body weight,
per os, suspended in water (2 ml/kg body
weight). Along with treated animals, an
equal number of control rats were dosed
with water in equivalent volumes for 14
days. Food was restricted from the control
rats to maintain comparable weights
between the groups because amiodarone
treatment causes a reduction in weight
gain. At the time the animals were ravaged,
the weights ofall the animals in the study
were within 30 g of each other. To main-
tain the phospholipidotic condition, the
amiodarone (and water-control) treatments
continued after the intratracheal instilla-
tions of silica or saline vehicle until the
animals were ravaged.
We measured drug levels in the AMs
recovered from the animals treated for 14
days with amiodarone using HPLC as
described by Reasor et al. (9). For the
phospholipid assay, samples of cell-free
bronchoalveolar lavage fluid and alveolar
macrophages recovered from the animals
treated for 14 days with amiodarone were
extracted with chloroform/methanol (2/1,
v/v) as described by Folch et al. (30). Total
lipid phosphorous in the cells and the
bronchoalveolar lavage fluid was quantified
by the method of Ames and Dubin (31)
following ashing in 10% MgNO3 in 70%
ethanol to liberate inorganic phosphorous
from the lipid.
Before silica was instilled in the ani-
mals, it was cleaned by boiling in 1.0 M
HCl for 60 min. The silica was suspended
and sonicated for 15 min in 0.9% sterile
saline at a concentration such that each rat
received a constant dose volume of 0.5 ml
per rat. One-half of all rats used in this
study were dosed intratracheally with a sin-
gle instillation of 2.5 mg or 10 mg/100 g
body weight of silica with a mean particle
size of<5 pm. In some preliminary studies,
these doses were shown to cause significant
acute toxicity. The remaining animals were
instilled with an equal volume of sterile
saline (vehicle control). We lightly anes-
thetized the rats by intraperitoneal injec-
tion of sodium methohexital, and using a
modified laryngoscope to illuminate the
larynx, intratracheally instilled each rat
with either the saline containing silica or
the saline vehicle.
On days 1 or 14 after instillation expo-
sure, bronchoalveolar lavage was per-
formed on the animals. The rats were
deeply anesthetized with an overdose of
sodium pentobarbital and exsanguinated
by severing the abdominal aorta. The lungs
ofeach rat were first ravaged with one sep-
arate aliquot of warm, calcium- and mag-
nesium-free Hanks' Balanced Salt Solution
(HBSS), pH 7.4, which was left in the
lungs for 30 sec, aspirated, reinstalled for
an additional 30 sec and then withdrawn.
We used a volume of 2.0 ml/100 g ofani-
mal body weight for this savage to take
into account any variations in body
weights of the rats ravaged. This lavage
sample was centrifuged at 5OOg for 7 min,
and the resultant cell-free supernatant was
analyzed for various biochemical parame-
ters. Additionally, the lungs were further
ravaged 10 times with 5-ml aliquots of
HBSS. These samples were also cen-
trifuged for 7 min at 5OOgand the cell-free
lavage fluid discarded. The cell pellets from
all washes for each rat were combined,
washed, and resuspended in 2 ml ofHBSS
buffer. We then counted and differentiated
the cells.
Total cell numbers were determined
using a hemacytometer. Using a Shandon
cytospin centrifuge, 1.5 x 10 cells were
spun for 4 min at 400 rpm and pelleted
onto a slide. Cells (200/rat) were differen-
tiated on the cytocentrifuge-prepared slides
after staining with Wright Giemsa Sure
Stain (Fisher Scientific, Pittsburgh,
Pennsylvania). AMs, neutrophils, and lym-
phocytes were counted.
We determined the protein content of
cell-free bronchoalveolar lavage fluid sam-
ples by the method of Hartree (32) using
bovine serum albumin as the standard. We
assayed 9-glucuronidase activity in the cell-
free bronchoalveolar lavage fluid by the
method ofLockard and Kennedy (33).
To determine the amount ofphospho-
lipid bound to silica in the lungs ofcontrol
and phospholipidotic rats, control and
amiodarone-treated rats were intratracheal-
ly instilled with a single 10 mg/100 g body
weight dose of silica as described above.
Bronchoalveolar lavage was performed on
the animals 1 day after the silica instilla-
tions. We used HBSS to lavage cells and
silica from the lungs ofthe animals. A total
of80 ml oflavage fluid was recovered from
each animal and centrifuged at 1 Og for 3
min. The resulting pellet for each rat was
washed and resuspended in 0.5 ml HBSS.
The cell/silica suspension was placed on
top of a 1.0 ml dibutyl phthalate (d =
1.080 g/ml) cushion in a microfuge tube.
To separate the silica from the cells, we
spun the suspensions in a Beckman
Microfuge (Beckman Instruments, Palo
Alto, California) at a setting of 2 for 30
sec. The lavage cells remained on top of
the cushion, while the silica particles
formed a pellet on the bottom ofthe tube.
The cushion was drawn off by a Pasteur
pipette. The pellet was washed with saline
twice. A 2:1 volume/volume mixture of
chloroform and methanol was added to the
pellet and vortexed for 30 sec to extract the
phospholipid from the silica. We included
a blank which contained 20 mg silica not
instilled in the animals. The samples were
then spun in the microfuge for 5 min at a
setting of 10. For analysis of total phos-
pholipid associated with the silica, 100-pl
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Figure 1. The accumulation of amiodarone and its
principal metabolite, desethylamiodarone, from
cells recovered from the lungs of rats. Animals
were treated for 14 days with an oral 150 mg/kg
daily dose of amiodarone. Values are means ± SE
(n= 4).
aliquots of the supernatant were added to
glass tubes in duplicate and dried
overnight. We quantified total lipid phos-
phorous by the method of Ames and
Dubin (31) as described above. An empty
microfuge tube was weighed before sepa-
rating the silica on the phthalate cushion.
The phthalate was removed, the lipid was
extracted from the silica, and the silica was
dried. We then weighed the microfuge
tube with the silica pellet. The previous
weight of the empty microfuge tube was
subtracted from this value for the measure-
ment of the amount of silica recovered
from the lungs of the animals. The phos-
pholipid content ofeach sample was deter-
mined as pmol/mg silica.
In Vitro CellViability Study
The rats were treated daily for 14 days
with 150 mg amiodarone or water/kg of
body weight, per os (pair-fed controls), as
described above. AMs were recovered from
control and amiodarone-treated animals by
pulmonary lavage. The cells were resus-
pended in sterile culture medium (34) and
plated at a concentration of 1.0 x 106
cells/tissue culture well. We incubated
AMs from amiodarone-treated and control
animals with a 0.5 mg/ml concentration of
native silica or silica coated with the
Survanta. The surfactant-treated silica was
prepared by suspending the silica in
Survanta and incubating for 1 hr at 37°C.
The excess surfactant was removed from
the silica by centrifugation at 5OOg for 10
min according to the method ofWallace et
al. (35). The supernatant was removed, the
silica was washed with HBSS by centrifu-
gation, and then resuspended in HBSS.
The amount of surfactant phospholipid
bound from this procedure was 0.012
0.002 pmol/mg silica (n = 4).
We incubated cells with the native or
surfactant-coated silicas for 24, 48, and 72
hr at 37°C in a tissue incubator containing
Figure 2. Total phospholipid content of the cells
recovered from the lungs of control and amio-
darone-treated rats. Animals were treated for 14
days with an oral 150 mg/kg daily dose of amio-
darone. The pair-fed control animals received
water. Values are means ± SE (n = 6). Mean value
of the phospholipid content of the amiodarone-
treated animals was significantly greater than
control value (*p <0.05).
air and 5% carbon dioxide. After incuba-
tion, a 0.10% final concentration of
trypsin was added to each well, and the
plates were incubated for 5 min to remove
attached alveolar macrophages. Cell viabili-
ty was measured on aliquots from each
well by trypan blue exclusion.
Statistical Analysis
Comparisons between the phospholipid
levels ofthe two treatment groups (Figs. 2,
3, 8) were made by the Student's t-test
analysis. For Figures 4-7 and Table 1,
comparisons were made among the differ-
ent treatment groups used. The signifi-
cance of the interaction among the treat-
ment groups was analyzed by using two-
way analysis of variance for each time
point at each dose. If significance was
observed, the significance between each of
the individual groups was analyzed by one-
way analysis of variance using a Duncan's
Figure 3. Total phospholipid content of the acellu-
lar bronchoalveolar lavage fluid (BALF) recovered
from the lungs of control and amiodarone-treated
rats. Animals were treated for 14 days with an oral
150 mg/kg daily dose of amiodarone. The pair-fed
control received water. Values are means ± SE (n
= 6). Mean value ofthe phospholipid content ofthe
amiodarone-treated animals was significantly
greaterthan control value (*p<0.05).
Multiple Range Test. The criterion for sig-
nificance was p <0.05.
Results
The levels ofamiodarone and its principal
metabolite desethylamiodarone, were mea-
sured in the AMs recovered from the lungs
of animals treated for 14 days with 150
mg/kg/day of amiodarone (Fig. 1). The
14-day amiodarone treatment led to sub-
stantial accumulation of both amiodarone
and desethylamiodarone in AMs.
Treatment for 14 days with amiodarone
resulted in a fourfold increase in total
phospholipid in the cells (Fig. 2) and a
threefold increase in total phospholipid in
the extracellular lavage fluid (Fig. 3) recov-
ered from the lungs when compared with
control animals that received water vehicle.
Treatment with silica alone (W-SI) at
the two doses used in this study caused a
significant increase in the total protein lev-
8
I.
I-
Post-instillation exposure Post-instillation exposure
Figure 4. Total protein content ofthe cell-free bronchoalveolar lavage fluid from the lungs of rats 1 and 14
days after silica instillation (2.5 mg or 10 mg/100 g body weight). Half of the animals were pretreated for
14 days with an oral 150 mg/kg daily dose of amiodarone (AD). The control animals received water (W).
Silica or saline vehicle then were instilled intratracheally and AD administration continued. Values are
means ± SE (n = 4-8). At each time pointfor each silica dose used, groups with different symbols are sig-
nificantly different (p<0.05).
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els of the cell-free bronchoalveolar lavage
fluid 1 and 14 days after exposure (Fig. 4).
This increase was reduced significantly at
both time points in the A-SI group of ani-
mals, which were pretreated with amio-
darone and were then instilled with silica.
The protein levels of the group that
received both amniodarone and the high
dose of silica were, however, still elevated
significantly above the two control groups
(A-SA and W-SA). In contrast, when using
a 2.5 mg/100 g body weight dose of silica
and measuring the response 14 days after
exposure, the amiodarone-induced phos-
pholipidosis completely prevented the
increase in protein in bronchoalveolar
lavage fluid caused by the silica.
The W-SI groups, which received silica
alone at both doses, had significantly ele-
vated levels of fI-glucuronidase activity
within the cell-free bronchoalveolar lavage
fluid 1 and 14 days after exposure com-
pared to the W-SA control group (Fig. 5).
The presence of the amniodarone-induced
phospholipidosis (A-SI group) attenuated
the silica-induced rise in fI-glucuronidase
activity from both doses. This reduction in
fI-glucuronidase activity was greatest at the
low silica dose group, although in neither
group was it complete. One day after the
instillation exposure, the A-SA group that
received both amniodarone and saline had a
significantly elevated level of fl-glu-
curonidase activity.
Mean total cell counts for all treatment
groups are presented in Figure 6. Com-
pared to the W-SA group, significant
increases in total cell numbers were
observed for all time periods and dose regi-
mens in the A-SI and W-SI treatment
groups. Increases were also seen in the A-
SA group of animals except at 14 days in
the low silica dose experiment. These find-
ings indicate that both the silica and amio-
darone treatment can individually increase
the number of cells in the lavage fluid of
rats. The cell number from combined
amniodarone and silica treatments (A-SI
group) was not different from the W-SI
group ofanimals.
Compared to the W-SA groups, neu-
trophils were significantly increased in the
AD-SI and W-SI groups ofanimals at both
time points and silica doses (Fig. 7). This
influx ofneutrophils in the W-SI and A-SI
groups accounted for nearly all the increas-
es in total cells. A significant increase was
also seen in the A-SA group 1 day after the
instillation exposure when compared to the
W-SA group for the small dose silica
group.
In analysis ofother cell types, the W-SI
group also had significantly increased
numbers oflymphocytes in the lavage fluid
compared to the W-SA control (data not
shown). Amniodarone pretreatment did not
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Figure 8. Total phospholipid bound to silica parti-
cles recovered from the lungs of control and
amiodarone-treated rats. Animals were treated
for 14 days with an oral 150 mg/kg daily dose of
amniodarone (AD). The control animals received
water (W). Silica (10 mg/100 g body weight) then
was intratracheally instilled into each animal of
both groups. Values are means ± SE (n = 6). The
mean value of the phospholipid bound to silica
from the AD-silica group was significantly
greater than the value of the W-silica group
*P005).
protect against this response. No consistent
response pattern was observed when evalu-
ating the change in the number of AMs
(data not shown).
To measure the amount of phospho-
lipid bound to the silica, control and amio-
darone-treated animals were intratracheally
instilled with silica (10 mg/100 g body
weight). One day after the installation,
there was nearly a four-fold greater amount
of phospholipid associated with the silica
recovered from the animals that had devel-
oped amiodarone-induced pulmonary
phospholipidosis when compared with
control animals (Fig. 8).
In Vitro CellVilabilityStudy
In an attempt to determine the mechanism
by which amiodarone-induced pulmonary
phospholipidosis protects the lungs from
the damage caused by silica, an in vitro
experiment was performed. AMs from
amiodarone-treated and control animals
were incubated for 24, 48, and 72 hr with
native silica or silica treated with Survanta
(Table 1). When incubating the AMs from
both treatment groups without silica for all
three time points, cell viability was greater
than 97%, and no significant differences
were observed between the cells from the
two treatment groups. When the cells were
exposed to native silica, a dramatic and
equal loss ofviability was demonstrated in
the control and phospholipidotic AMs at
each of the three time points. In the cells
from the control group, the silica treated
with surfactant caused an exposure time-
dependent reduction in cell viability of
21%,5i1%, and 68% at 24, 48, and 72 hr,
respectively. The silica treated with surfac-
tant caused significantly less cytotoxicity to
the phospholipidotic AMs. A 7-10%
reduction in cell viability occurred for the
three time points.
Discussion
Studies have demonstrated that exposure
of rats to silica increases the intra- and
extracellular compartments of pulmonary
surfactant phospholipid (36-38). These
investigations have indicated that this ele-
vation in phospholipid is due to an
increase in the biosynthesis of the pul-
monary surfactant. It therefore appears
that the increase in pulmonary phospho-
lipid may be a mechanism by which the
lungs protect themselves when challenged
with silica. Clearly, an elevation in surfac-
tant alone is inadequate to protect against
toxicity, as massive damage occurs while
phospholipid levels are elevated (4,38);
however, by increasing the phospholipids
within the cells and airways within the
lungs before the insult, it may be possible
to reduce the damage caused by the expo-
sure to silica.
Vallyathan et al. (20) hypothesized that
the surface properties of silica may be
involved in its cytotoxicity. When silica is
inhaled, the free radicals present on the
surface of the silica can generate hydroxyl
radicals in the aqueous environment ofthe
lung, which may lead to the development
ofcellular damage.
Several in vitro studies have been per-
formed using phospholipids in an attempt
to coat the silica and reduce its cytotoxici-
ty. Emerson and Davis (21) coated silica
with alveolar lining material and compared
the cytotoxicity produced with uncoated
silica. They demonstrated that the coated
silica was effectively phagocytized by the
AMs but was less cytotoxic than uncoated
silica. Consequently, they concluded that
inhaled silica particles that become coated
by surfactant lipids may reduce or delay
the AM toxicity. In another in vitro study
by Wallace et al. (22), the biological
responses of dipalmitoyl lecithin-modified
and native silica were compared. The find-
ings ofthis investigation also indicated that
surface modification of the silica with
dipalmitoyl lecithin prevented the cytotox-
icityofsilica.
In another study by Schimmelpfeng et
al. (25), bovine and rat AMs were incubat-
ed in vitro with DQ12 quartz alone or in
the presence of dipalmitoyl lecithin. The
reaction of the cells of both species to the
untreated dust particles was similar qualita-
tively and quantitatively, with a loss ofvia-
bility and release of lactate dehydrogenase
after incubation. In the presence of
dipalmitoyl lecithin, the toxicity of quartz
to the bovineAMs disappeared completely,
while the rat AMs were also protected, but
to a lesser degree. While such in vitro
experiments are consistent with the
hypothesis that surfactant may play a pro-
tective role against silica-induced pul-
monary toxicity, the significance of this
process in vivo is unknown.
As we have demonstrated previously
(9,19,39), treatment of rats with amio-
darone resulted in pulmonary phospholipi-
dosis. This amiodarone pretreatment
caused a significant increase in the phos-
pholipid levels within AMs and the cell-
free bronchoalveolar lavage fluid. The pre-
sent study was performed to investigate
whether preexisting increased levels of
phospholipids in the lungs induced by
amiodarone would protect them from
acute damage caused by the intratracheal
instillation ofsilica.
Within the bronchoalveolar lavage fluid,
a variety of cellular and biochemical para-
meters were measured to characterize the
acute inflammatory response caused by sili-
ca. Markers of pulmonary damage within
the acellular component of the lavage fluid
were assayed. Total protein and {9-glu-
Table 1. Percent viability of alveolar macrophages from amiodarone-treated and water-treated rats after
incubation with native silica and silica treated with surfactanta
Treatment groups
Time H20b Amiodaroneb
24 hr Control 98.7 ± 0.6 98.5 ± 1.0
Silica 21.2 ± 2.8 28.2 ± 4.6
Silica + Survanta 78.9 ± 2.9 92.7 ± 2.6'
48 hr Control 98.3 ± 1.1 98.8 ± 0.8*
Silica 21.5 ±3.7* 23.4 ±4.8
Silica + Survanta 48.8 ± 4.4 92.3 ± 1.4'
72 hr Control 97.5 ± 0.5 99.3 ± 0.5
Silica 7.9 ±3.1* 12.3 ± 2.8
Silica + Survanta 32.6 ± 3.9 90.3 ± 2.3
aSee textfor methods.
b'Values are means ± SE (n = 4-5). At each time point forthe cells from both treatment groups, the mean
values of the percent viability for the two silica groups are significantly different than the values of their
respective controls and the silica + Survanta groups (*p<0.05); the mean values ofthe percentviability of
the two silica + Survanta groups are significantly different from their respective controls (**p<0.05); and
the mean values of the percent viability of the two silica + Survanta groups are significantly different
from each other(tp<0.05).
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curonidase activitywere analyzed. Total and
differential cell counts were also evaluated
on the cells recovered from the lungs. The
pneumotoxic response we demonstrated
with the silica instillation was consistent
with the study ofLindenschmidt et al. (4).
As in that study, pulmonary damage, as
measured biochemically, was still present 14
days after the silica instillations. When
using silica doses of2.5 mg and 10 mg/100
g body weight, the alveolar phospholipido-
sis produced by amiodarone pretreatment
markedly attenuated the elevations of the
acellular lavage parameters indicative of
damage after silica instillation. This protec-
tion, which was virtually complete with the
low silica dose, was consistent 1 and 14
days after the silica exposure for total pro-
tein and 9-glucuronidase activity.
In the assessment of the cellular para-
meters ofthe lavage fluid, the silica instilla-
tion, at both doses, caused an increase in
the number of cells recovered from the
lungs at the two time points after the expo-
sure. This elevation in cell numberwas due
largely to the influx ofneutrophils into the
lungs. Although the increased phospho-
lipids within the lungs reduced the bio-
chemical indices ofdamage caused by sili-
ca, it had no effect in preventing this infil-
tration of neutrophils. In the study by
Lindenschmidt et al. (4), aluminum oxide
and titanium dioxide increased the number
of neutrophils in the lungs, but caused a
significantly lower degree ofpneumotoxici-
ty when compared with silica. As there
were no differences in the cellular response
ofthe two silica groups used in this study,
it appears the silica is reaching the same
areas within the airspaces ofthe lung. This
indicates that the protective effect of the
phospholipidosis is probably not due to a
difference in distribution of silica in the
lungs as a result ofthis condition.
Neutrophils appear within the pul-
monary interstitium and the bronchoalveo-
lar savage fluid within a day after the intra-
tracheal instillation of silica. Chemotactic
substances released from AMs are a likely
explanation for the attraction of neu-
trophils to the lungs. The presence ofneu-
trophils in the lungs is important because
of their potent ability to cause lung tissue
injury (5). Thus, it appears that the chem-
otactic signal which recruits the neu-
trophils into the lungs was unaffected by
phospholipidosis. Given that neutrophils
have been implicated in silica-induced lung
injury (40), it is conceivable that treatment
with amiodarone either directly or indi-
rectly renders them less active.
Pulmonary surfactant, which is 90-
95% phospholipid, forms an insoluble film
on the surface of the alveoli of the lungs
(41). It is possible that an increase in the
amount of phospholipid coating the silica
particles in the phospholipidotic lungs may
be involved in the protection against acute
silica damage. To further investigate this
idea, silica was intratracheally instilled into
the lungs of either control rats or amio-
darone-treated rats that had developed pul-
monary phospholipidosis. We found that
there was a fourfold greater amount of
phospholipid associated with the silica
removed from the lungs that had devel-
oped phospholipidosis when compared
with normal lungs. However, there was
still a measurable amount ofphospholipid
bound to the silica recovered from the con-
trol lungs. Therefore, the presence of a
phospholipid coating alone on silica is
inadequate to protect against damage.
It may be that a silica particle that has
adsorbed surfactant is phagocytized by the
AMs without an immediate cytotoxic
effect. The coated particle then may be
subjected to phospholipase activity associ-
ated with the AMs. These enzymes have
been shown to be active on components of
surfactant. Hostetler et al. (42) indicated
that phospholipases can hydrolyze phos-
pholipids, such as dipalmitoyl lecithin, pre-
sent in surfactant. Thus, the removal ofthe
phospholipid coating ofthe silica by phos-
pholipases may retoxify the silica, resulting
in damage to theAMs.
When AMs were incubated for 24, 48,
and 72 hr with native silica, the control
and phospholipidotic AMs were equally
sensitive to the cytotoxic action ofthe par-
ticles. Therefore, the presence of elevated
phospholipid within the phospholipidotic
cells provided no protection against the
cellular injury caused by silica. The phos-
pholipidotic cells were, however, more
resistant to the cytotoxic action ofthe sur-
factant-coated silica than were the control
AMs. When exposed to surfactant-coated
silica, control cells lost viability in a time-
dependent manner, while the phospholipi-
dotic cells were virtually unaffected over
the 3-day period. It may be that over the
exposure period, control alveolar macro-
phages digest a portion of the surfactant
from the surface of the silica, in effect
retoxifying the particles, resulting in loss of
cellular viability. Thus, the presence of a
surfactant coating on the silica particles
would delay, but not prevent, the cytotoxi-
city of silica. Within the phospholipidotic
cells, the inhibition oflysosomal phospho-
lipases by amiodarone and desethylamio-
darone effectively prevents digestion of
adsorbed surfactant from the silica, thus
preventing retoxification from occurring.
This scenario would be consistent with the
reduced cytotoxicity of surfactant-coated
silica toward the phospholipidotic cells and
offers an explanation for the protective
effect of the phospholipidosis against the
acute toxicity ofSilica in vivo.
The significance ofphospholipase inhi-
bition is further illustrated by the fact that
the amount ofsurfactant bound to the sili-
ca in this experimental in vitro condition
was less than we measured on silica recov-
ered from control animals where damage
was the greatest. This would suggest that
the increased quantity of phopholipid
bound to the silica in the phospholipidotic
rats may be of less significance than the
cellular phospholipase inhibition in pro-
tecting against acute silica toxicity in this
model.
In a recent editorial, Hook (43) specu-
lated whether pulmonary surfactant plays a
role in the defense ofthe lungs. The results
ofthis study would support the idea that a
sustained elevation in acellular phospho-
lipid in the airspaces and alveoli occurring
before silica exposure may delay the acute
toxicityofthis dust.
The results of this study, however, are
only applicable for silica's acute toxic
response. The influence ofthe reduction in
the initial pneumotoxic response to silica
by the phospholipidosis on the eventual
development offibrosis is unknown.
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